RxDoctor Payments Data

Kathleen Viola, MD

Dermatology · Sparks Glencoe, MDNPI 1083971436

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Johnson & Johnson accounts for 64.1% of it on its own, with 29 other manufacturers making up the rest. Among dermatology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,675in general payments, 2019–2025

Across 829 payments — averaging $47.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$25K
  • AbbVie$2K
  • Organon$2K
  • EPI Health, LLC$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Sanofi$1K
  • plus $7K from 24 others

What the payments were for

  • Consulting fees$20,30051%
  • Travel & lodging$4,13410%
  • Food & beverage$14,53937%
  • Education$7022%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,675 in reported general payments places this provider in the 90th percentile of 306 dermatology providers in Maryland.

See all dermatology providers in Maryland

Medicare billing

Part B allowed, 2024
$124,043
Medicare patients
285
Services billed
1,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab14$51,670
OpzeluraRuxolitinib Phosphate13$24,392
Tacrolimus33$4,835
Clobetasol Propionate50$3,327
Fluocinonide47$1,697
Ketoconazole94$1,373
Metronidazole29$1,216
Doxycycline Hyclate69$1,001
Clindamycin Phosphate17$884
Ammonium Lactate32$726
Triamcinolone Acetonide60$724
Nystatin50$635
Fluconazole29$275
Mometasone Furoate14$237
Minoxidil22$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$456$24,39213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 306 dermatology providers in Maryland.

Other dermatology in Sparks Glencoe

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →